Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold

被引：36

作者：

Jones, Eric D. ^{[1
]}

Vandegraaff, Nick ^{[1
]}

Le, Giang ^{[1
]}

Choi, Neil ^{[1
]}

Issa, William ^{[1
]}

Macfarlane, Katherine ^{[1
]}

Thienthong, Neeranat ^{[1
]}

Winfield, Lisa J. ^{[1
]}

Coates, Jonathan A. V. ^{[1
]}

Lu, Long ^{[2
]}

Li, Xinming ^{[2
]}

Feng, Xiao ^{[2
]}

Yu, Changjiang ^{[2
]}

Rhodes, David I. ^{[1
]}

Deadman, John J. ^{[1
]}

机构：

[1] Avexa Ltd, Richmond, Vic 3121, Australia

[2] Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 19期

关键词：

Integrase; Inhibitor; Synthesis; 3-Hydroxy-pyrido[12-a]pyrimidin-4-one;

D O I：

10.1016/j.bmcl.2010.07.079

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

HIV integrase inhibitors based on a novel bicyclic pyrimidinone core is presented. Nine variations of the core scaffold are evaluated leading to optimization of the 6:6 core giving compound 48 with an EC50 of 3 nM against wild type HIV infected T-cells. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：5913 / 5917

页数：5

共 50 条

[1] Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: Azoles: Effective metal chelators
Le, Giang
Vandegraaff, Nick
Rhodes, David I.
Jones, Eric D.
Coates, Jonathan A. V.
Thienthong, Neeranat
Winfield, Lisa J.
Lu, Long
Li, Xinming
Yu, Changjiang
Feng, Xiao
Deadman, John J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (19) : 5909 - 5912
[2] An Isoquinoline Scaffold as a Novel Class of Allosteric HIV-1 Integrase Inhibitors
Wilson, Tyler A.
Koneru, Pratibha C.
Rebensburg, Stephanie V.
Lindenberger, Jared J.
Kobe, Matthew J.
Cockroft, Nicholas T.
Adu-Arnpratwum, Daniel
Larue, Ross C.
Kvaratskhelia, Mamuka
Fuchs, James R.
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (02): : 215 - 220
[3] Design and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors
Hu, Liming
Zhang, Sulei
He, Xianzhuo
Luo, Zaigang
Wang, Xiaoli
Liu, Wei
Qin, Xuemei
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (01) : 177 - 182
[4] De novo design and synthesis of HIV-1 integrase inhibitors
Makhija, MT
Kasliwal, RT
Kulkarni, VM
Neamati, N
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (09) : 2317 - 2333
[5] Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors
Wang, Yujie
Rong, Jie
Zhang, Bin
Hu, Liming
Wang, Xiaoli
Zeng, Chengchu
BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (04) : 735 - 741
[6] Clinical progress of HIV-1 integrase inhibitors
Al-Mawsawi, Laith Q.
Al-Safi, Rasha I.
Neamati, Nouri
EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (02) : 213 - 225
[7] Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase
de Soultrait, VR
Desjobert, C
Tarrago-Litvak, L
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (18) : 1765 - 1778
[8] 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position
Johns, Brian A.
Weatherhead, Jason G.
Allen, Scott H.
Thompson, James B.
Garvey, Edward P.
Foster, Scott A.
Jeffrey, Jerry L.
Miller, Wayne H.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (06) : 1807 - 1810
[9] HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants
Smith, Steven J.
Zhao, Xue Zhi
Passos, Dario Oliveira
Lyumkis, Dmitry
Burke, Terrence R., Jr.
Hughes, Stephen H.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (09)
[10] Design of inhibitors of the HIV-1 integrase core domain using virtual screening
Regon, Preetom
Gogoi, Dhrubajyoti
Rai, Ashok Kumar
Bordoloi, Manabjyoti
Bezbaruah, Rajib Lochan
BIOINFORMATION, 2014, 10 (02) : 76 - 80

← 1 2 3 4 5 →